Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100

(RTTNews) - Pulmatrix, Inc. (PULM) announced the FDA has accepted the PUR3100 investigational new drug application and the company has received a study may proceed letter for a phase 2, randomized, double-blind, placebo-controlled, single event study to evaluate PUR3100 in the acute treatment of Migraine. The PUR3100 formulation uses Pulmatrix's dry powder delivery technology, iSPERSE to deliver DHE via oral inhalation using a dry powder inhaler.

Ted Raad, CEO of Pulmatrix, said: "We are currently pursuing options to advance PUR3100 into a Phase 2 clinical trial to investigate PUR3100 efficacy, safety, tolerability in treating acute migraine subjects."

Shares of Pulmatrix are up 9% in pre-market trade on Tuesday.

For More Such Health News, visit rttnews.com.